Loan & DebtJun 17, 2026, 07:32 AM
Dyne Therapeutics Secures Up to $125M Additional Loan Capacity
AI Summary
Dyne Therapeutics, Inc. announced an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc., securing up to $125 million in additional borrowing capacity. $50 million was funded immediately, with another $50 million available upon achieving certain milestones and a final $25 million at Hercules Capital's discretion. This additional capital strengthens Dyne's balance sheet, supporting the advancement of its clinical programs, zeleciment rostudirsen and zeleciment basivarsen, through critical clinical and regulatory milestones and preparing for two potential U.S. launches in the next two years.
Key Highlights
- Dyne Therapeutics secured up to $125 million in additional borrowing capacity.
- $50 million was funded immediately upon execution of the amendment.
- An additional $50 million tranche is available upon achieving certain milestones.
- The final tranche was increased by $25 million, providing up to an additional $75 million.
- Aggregate borrowed loan proceeds now total $200 million.
- The company maintains access to up to $200 million in potential future funding.
- Funds will advance zeleciment rostudirsen and zeleciment basivarsen through clinical and regulatory milestones.
- The capital enhances financial flexibility for two potential U.S. launches in the next two years.
Price Impact
More from DYN